BSE Live
Mar 23, 16:01Prev. Close
4771.55
Open Price
4645.05
Bid Price (Qty.)
4525.00 (10)
Offer Price (Qty.)
4645.00 (10)
NSE Live
Mar 23, 15:51Prev. Close
4773.50
Open Price
4770.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Pfizer (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 16 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 1,900.76 | 1,057.43 | 995.09 | 1,058.32 | 1,215.01 | |
| Less: Excise/Sevice Tax/Other Levies | 73.02 | 53.15 | 47.11 | 41.02 | 45.45 | |
| Revenue From Operations [Net] | 1,827.74 | 1,004.27 | 947.98 | 1,017.30 | 1,169.56 | |
| Total Operating Revenues | 1,853.32 | 1,111.81 | 1,050.07 | 1,095.44 | 1,252.45 | |
| Other Income | 67.35 | 109.38 | 105.24 | 90.56 | 92.90 | |
| Total Revenue | 1,920.66 | 1,221.19 | 1,155.31 | 1,186.00 | 1,345.35 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 385.84 | 265.77 | 238.49 | 230.77 | 272.65 | |
| Purchase Of Stock-In Trade | 436.38 | 106.27 | 97.23 | 146.81 | 149.99 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -82.36 | 2.84 | -2.67 | -18.49 | -32.15 | |
| Employee Benefit Expenses | 236.36 | 191.77 | 206.70 | 189.63 | 226.99 | |
| Finance Costs | 0.77 | 0.36 | 0.24 | 1.91 | 2.47 | |
| Depreciation And Amortisation Expenses | 131.08 | 7.97 | 8.02 | 9.56 | 12.00 | |
| Other Expenses | 494.14 | 306.62 | 323.23 | 347.90 | 365.76 | |
| Total Expenses | 1,602.20 | 881.60 | 871.24 | 908.10 | 997.71 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 318.46 | 339.59 | 284.07 | 277.90 | 347.65 | |
| Exceptional Items | -80.45 | 0.00 | 409.69 | -0.38 | -3.03 | |
| Profit/Loss Before Tax | 238.02 | 339.59 | 693.77 | 277.53 | 344.62 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 151.00 | 113.04 | 195.43 | 94.47 | 126.32 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -13.32 | 5.68 | -4.86 | -1.55 | -8.04 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 137.68 | 118.73 | 190.57 | 92.92 | 118.28 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 100.34 | 220.86 | 503.20 | 184.61 | 226.34 | |
| Profit/Loss From Continuing Operations | 69.82 | 220.86 | 503.20 | 184.61 | 226.34 | |
| Profit/Loss For The Period | 69.82 | 220.86 | 503.20 | 184.61 | 226.34 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 21.93 | 74.01 | 168.63 | 56.78 | 68.69 | |
| Diluted EPS (Rs.) | 21.93 | 74.01 | 168.63 | 56.78 | 68.69 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 150.29 | 79.91 | 73.83 | 60.08 | 71.01 | |
| Indigenous Raw Materials | 139.54 | 113.77 | 98.75 | 99.75 | 123.79 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 57.18 | 1,074.29 | 96.99 | 37.30 | 49.24 | |
| Tax On Dividend | 11.64 | 182.58 | 16.48 | 6.05 | 7.99 | |
| Equity Dividend Rate (%) | 125.00 | 3,600.00 | 325.00 | 125.00 | 165.00 |
10.02.2026
Pfizer Standalone December 2025 Net Sales at Rs 645.03 crore, up 19.9% Y-o-Y
13.11.2025
Pfizer Standalone September 2025 Net Sales at Rs 642.34 crore, up 9.13% Y-o-Y
20.05.2025
Pfizer Standalone March 2025 Net Sales at Rs 591.91 crore, up 8.28% Y-o-Y
01.02.2025
Pfizer Standalone December 2024 Net Sales at Rs 537.99 crore, down 0.37% Y-o-Y
19.10.2016
05.08.2016
03.01.2014
10.01.2011
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth